Abstracts Archive - Page 544 of 2425 - ACR Meeting Abstracts

Abstract Number: 1665 • ACR Convergence 2021
Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis
Sarah Patterson¹, Shenghuan Sun², Dmitry Rychkov², Alexandra Tsitsiklis², Paula Hayakawa Serpa², Patricia Katz², Charles Langelier² and Marina Sirota², ¹University of California San Francisco, Pacifica, CA, ²University of California San Francisco, San Francisco, CA
Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
Abstract Number: 1680 • ACR Convergence 2021
Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials
Grace Wright¹, Eduardo Mysler², Yi-Hsing Chen³, Cassandra Kinch⁴, Arne Yndestad⁵, Kenneth Kwok⁶, Mary Jane Cadatal⁷, Rebecca Germino⁸ and Alexis Ogdie⁹, ¹Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Canada ULC, Kirkland, QC, Canada, ⁵Pfizer Inc, Oslo, Norway, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Manila, Philippines, ⁸Pfizer Inc, Groton, CT, ⁹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
Abstract Number: 1688 • ACR Convergence 2021
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis
Peter C Taylor¹, Tsutomu Takeuchi², Gerd Burmester³, Patrick DUREZ⁴, Josef Smolen⁵, Walter Deberdt⁶, Jinglin Zhong⁷, Jorge Ross Terres⁶, Natalia Bello⁶ and Kevin Winthrop⁸, ¹University of Oxford, Oxford, United Kingdom, ²Div. Rheumatology, Keio University, Tokyo, Japan, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, ⁵Medical University of Vienna, Vienna, Austria, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷IQVIA, Morrisville, NC, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of adult patients with moderately to severely active rheumatoid…
Abstract Number: 1697 • ACR Convergence 2021
Clinical Outcomes up to Week 48 of Filgotinib Treatment in an Ongoing Long-term Extension Trial of RA Patients with Inadequate Response to MTX Initially Treated with Filgotinib or Adalimumab During the Phase 3 Parent Trial
Bernard Combe¹, Yoshiya Tanaka², Paul Emery³, Alena Pechonkina⁴, Albert Kuo⁴, Qi Gong⁴, Katrien Van Beneden⁵, Vijay Rajendran⁶ and Hendrik Schulze-Koops⁷, ¹CHU Montpellier Montpellier University, Montpellier, France, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos, NV, Mechelen, Belgium, ⁶Galapagos NV, Mechelen, Belgium, ⁷Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. We assessed…
Abstract Number: 1694 • ACR Convergence 2021
Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL, ⁶Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…
Abstract Number: 1652 • ACR Convergence 2021
Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis
Paul Studenic¹, Alexandra Circiumaru², Daniel Aletaha³, Katerina Chatzidionysiou⁴, Anca Catrina⁵ and Aase Haj Hensvold⁶, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ³Medical University Vienna, Vienna, Austria, ⁴Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, ⁵Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
Abstract Number: 1670 • ACR Convergence 2021
Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam², Ben Ponvilawan³, Pitchaporn Yingchoncharoen³ and Jerapas Thongpiya⁴, ¹Cleveland Clinic, Cleveland Heights, OH, ²Mount Auburn Hospital, Boston, MA, ³Mahidol University, Bangkok, Thailand, ⁴Mahdiol University, Bangkok, Thailand
Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
Abstract Number: 1710 • ACR Convergence 2021
Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
Daniel Aletaha¹, Rene Westhovens², Tatsuya Atsumi³, YingMeei Tan⁴, Alena Pechonkina⁵, Qi Gong⁵, Vijay Rajendran⁶, Sander Strengholt⁷ and Gerd Burmester⁸, ¹Medical University Vienna, Vienna, Austria, ²University Hospitals KU Leuven, Maaseik, Belgium, ³Hokkaido University, Sapporo, Japan, ⁴Gilead Sciences, Inc, San Diego, CA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos, BV, New York, NY, ⁸Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. In this…
Abstract Number: 1709 • ACR Convergence 2021
Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial
Min Jung Kim¹, Eun Hye Park² and Kichul Shin³, ¹Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ²Chung-Ang University Hospital, Seoul, Republic of Korea, ³Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: Mesenchymal stem cell (MSC) therapy represents a promise for the treatment of autoimmune diseases due to its potent immunomodulatory effect. We investigated the long-term…
Abstract Number: 1705 • ACR Convergence 2021
The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users
Marco Gianpiero Antivalle¹, Michele Agosti¹, Giuliana La Paglia², Alberto Batticciotto³, Maria Chiara Ditto⁴, SIMONE PARISI⁵ and Piercarlo Sarzi-Puttini⁶, ¹L. Sacco University Hospital, Milano, Italy, ²L.Sacco University Hospital, Milano, Lombardia, Italy, ³Ospedale di Circolo - Fondazione Macchi, Varese, Lombardia, Italy, ⁴AOU Città della Salute e della Scienza, Torino, Italy, ⁵AOU Città della Salute e della Scienza, TURIN, Italy, ⁶L.Sacco University Hospital, Milano, Italy
Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has…
Abstract Number: 1699 • ACR Convergence 2021
The “ITIS” Diet Improves Fatigue in Patients with Rheumatoid Arthritis and Is Associated with Changes in Metabolome and Fecal Microbiome
Roxana Coras¹, Cameron Martino¹, Julia Gauglitz¹, Alan Jarmusch¹, Anupriya Tripathi¹, Francesca Cedola², Marta Fernandez-Bustamante¹, Meritxall Agustín-Perez¹, Maram Alharthi¹, Susan Lee¹, Abha Singh¹, Soo In Choi¹, Tania Rivera¹, Katherine Nguyen³, Tatyana Shekhtman¹, Tiffany Holt¹, Shahrokh Golshan¹, Rob Knight¹, Pieter C Dorrestein¹ and Monica Guma¹, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, Rome, CA, Italy, ³University of California San Diego, San Diego, CA
Background/Purpose: Fatigue is common symptom in rheumatoid arthritis (RA), associated with decreased quality of life and productivity. Fatigue mechanisms have not been well studied, hence,…
Abstract Number: 1708 • ACR Convergence 2021
The Efficacy and Safety of Piclidenoson vs Methotrexate in Early Rheumatoid Arthritis: Phase 3 Randomized, Double-blind, Placebo-controlled Study
Tatiana Reitblat¹, Alexandra Gurman- Balbir², Zivit Harpaz³, Motti Farbstein³, Michael Silverman³, William Kerns³ and Pnina Fishman³, ¹Barzilai Medical Center, Ashkelon, Israel, ²Rambam Medical Center, Haifa, Israel, ³Can-Fite BioPharma, Petah Tikva, Israel
Background/Purpose: Piclidenoson, a highly selective A3 adenosine receptor (A3AR) agonist, demonstrated safety and efficacy in phase 2 clinical studies in rheumatoid arthritis (RA) and psoriasis.…
Abstract Number: 1691 • ACR Convergence 2021
Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Gerd Burmester¹, Stanley Cohen², Kevin Winthrop³, Peter Nash⁴, Andrea Rubbert-Roth⁵, Atul Deodhar³, Ori Elkayam⁶, Eduardo Mysler⁷, Yoshiya Tanaka⁸, Jianzhong Liu⁹, Ana Paula Lacerda⁹, Bosny Pierre-Louis⁹, Tim Shaw¹⁰ and Philip Mease¹¹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Metroplex Clinical Research Center, Dallas, TX, ³Oregon Health & Science University, Portland, OR, ⁴Griffith University, Brisbane, Australia, ⁵Kantonspital St Gallen, St.Gallen, Switzerland, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: The efficacy and safety of the oral Janus kinase inhibitor, upadacitinib (UPA), has been evaluated for several rheumatic diseases. The objective of this analysis…
Abstract Number: 1703 • ACR Convergence 2021
AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis
Thomas Jonassen¹, Thierry Duvauchelle¹, Birgitte Telmer², Irene Sandholdt², Thomas Boesen¹ and Ellen-Margrethe Hauge³, ¹SynAct Pharma, Holte, Denmark, ²CroxxMed, Hørsholm, Denmark, ³Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Melanocortin (MC) type 1 and type 3 receptor stimulation is associated with anti-inflammation and promotion of inflammatory resolution. AP1189 is a biased MC type…
Abstract Number: 1695 • ACR Convergence 2021
Erythrocyte Methotrexate Polyglutamates Are Substantially Higher After Subcutaneous Methotrexate Treatment in Rheumatoid Arthritis Patients in the First Months of Treatment
Renske Hebing¹, Sohaila Mahmoud¹, Marry Lin², Ittai Muller², Sandra Heil³, Willem Lems⁴, Mike Nurmohamed⁵, Robert de Jonge² and Gerrit Jansen², ¹Reade, Amsterdam, Netherlands, ²AmsterdamUMC, Amsterdam, Netherlands, ³ErasmusMC, Rotterdam, Netherlands, ⁴VUmc, Amsterdam, Netherlands, ⁵Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Optimal dosing of methotrexate (MTX) for individual rheumatoid arthritis (RA) patients to achieve adequate disease control remains challenging. Assessment of erythrocyte MTX-polyglutamates (PGs) levels…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].